Trends in pneumococcal bacteraemia in adults after the beginning of a pneumococcal vaccination programme
Abstract number: 1733_588
Peralta G., Ceballos B., Sanchez M., Fariñas C., De Benito I., Roiz M., Ansorena L.
Objectives: In Cantabria (Spain) a polysaccharide pneumococcal vaccination programme has been initiated in the year 2000, directed to people older than 65 years and/or with specific comorbidities. We analyze changes in incidence and characteristics of pneumococcal bacteraemia (PB) in our hospital after the beginning of the pneumococcal vaccination programme.
Methods: Retrospective review of all charts of patients with PB identified by using the microbiology database, attended in our hospital from January 1997 to December 2005. We compared the periods 19972000 (prevaccination) and 20012005 (postvaccination). In statistical analyses, Mann-Whitney U test was used for the comparison of mean values and Chi-square test for the comparison of categorical data.
Results: In the period of study we detected 118 PB. The annual incidence 8.2 cases per 100000 population. No significant differences were detected among prevaccine and postvaccine periods in the age, the presence of any comorbidity, the origin of the bacteraemia or the outcome of patients with PB. A decrease in the proportion of PB caused by penicillin non-susceptible pneumococci in the postvaccination period was detected. Although no significant difference was detected in the global PB incidence among prevaccine and postvaccine period, both the number of annual PB respect to the hospital admissions and the number of annual PB respect blood cultures performed diminished in the postvaccine period.
Conclusions: Our data suggest that PB has decreased after the beginning of a pneumococcal vaccination programme, with an associated decline in penicillin non-susceptibility. No change in other characteristics of patients with PB has detected after the beginning of the programme.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|